Jiangsu Nhwa Pharmaceutical Past Earnings Performance
Past criteria checks 4/6
Jiangsu Nhwa Pharmaceutical has been growing earnings at an average annual rate of 11.9%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 8.4% per year. Jiangsu Nhwa Pharmaceutical's return on equity is 16.4%, and it has net margins of 21.2%.
Key information
11.9%
Earnings growth rate
11.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 8.4% |
| Return on equity | 16.4% |
| Net Margin | 21.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Oct 28
Is Now The Time To Put Jiangsu Nhwa Pharmaceutical (SZSE:002262) On Your Watchlist?
Oct 21Jiangsu Nhwa Pharmaceutical (SZSE:002262) Has A Rock Solid Balance Sheet
Sep 20The Market Doesn't Like What It Sees From Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) Earnings Yet
Sep 04Here's Why Jiangsu Nhwa Pharmaceutical (SZSE:002262) Has Caught The Eye Of Investors
Jul 22Jiangsu Nhwa Pharmaceutical (SZSE:002262) Seems To Use Debt Rather Sparingly
Jun 16Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) Share Price Is Matching Sentiment Around Its Earnings
May 09Jiangsu Nhwa Pharmaceutical (SZSE:002262) Ticks All The Boxes When It Comes To Earnings Growth
Apr 18Earnings Update: Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts
Apr 02Revenue & Expenses Breakdown
How Jiangsu Nhwa Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 5,531 | 1,171 | 2,139 | 600 |
| 30 Jun 24 | 5,405 | 1,121 | 2,027 | 613 |
| 31 Mar 24 | 5,220 | 1,075 | 1,979 | 583 |
| 31 Dec 23 | 5,042 | 1,037 | 1,959 | 549 |
| 30 Sep 23 | 4,834 | 1,044 | 1,885 | 548 |
| 30 Jun 23 | 4,698 | 998 | 1,943 | 501 |
| 31 Mar 23 | 4,485 | 939 | 1,910 | 463 |
| 01 Jan 23 | 4,299 | 901 | 1,849 | 454 |
| 30 Sep 22 | 4,164 | 867 | 1,847 | 408 |
| 30 Jun 22 | 4,072 | 834 | 1,810 | 387 |
| 31 Mar 22 | 4,024 | 819 | 1,743 | 385 |
| 01 Jan 22 | 3,936 | 798 | 1,750 | 352 |
| 30 Sep 21 | 3,879 | 830 | 1,638 | 308 |
| 30 Jun 21 | 3,744 | 787 | 1,587 | 301 |
| 31 Mar 21 | 3,528 | 759 | 1,516 | 277 |
| 31 Dec 20 | 3,361 | 729 | 1,445 | 246 |
| 30 Sep 20 | 3,326 | 714 | 1,435 | 236 |
| 30 Jun 20 | 3,534 | 694 | 1,498 | 214 |
| 31 Mar 20 | 3,837 | 675 | 1,622 | 185 |
| 31 Dec 19 | 4,149 | 663 | 1,664 | 189 |
| 30 Sep 19 | 4,167 | 623 | 1,608 | 182 |
| 30 Jun 19 | 4,090 | 585 | 1,512 | 181 |
| 31 Mar 19 | 3,981 | 549 | 1,421 | 178 |
| 31 Dec 18 | 3,858 | 525 | 1,350 | 172 |
| 30 Sep 18 | 3,764 | 472 | 1,173 | 149 |
| 30 Jun 18 | 3,581 | 447 | 1,077 | 179 |
| 31 Mar 18 | 3,482 | 411 | 1,082 | 146 |
| 31 Dec 17 | 3,394 | 395 | 1,066 | 111 |
| 30 Sep 17 | 3,274 | 400 | 1,121 | 79 |
| 30 Jun 17 | 3,181 | 347 | 1,164 | 0 |
| 31 Mar 17 | 3,097 | 325 | 1,085 | 0 |
| 31 Dec 16 | 3,018 | 310 | 1,005 | 0 |
| 30 Sep 16 | 3,004 | 297 | 963 | 0 |
| 30 Jun 16 | 2,937 | 284 | 880 | 0 |
| 31 Mar 16 | 2,851 | 269 | 856 | 0 |
| 31 Dec 15 | 2,767 | 258 | 817 | 0 |
| 30 Sep 15 | 2,694 | 257 | 760 | 0 |
| 30 Jun 15 | 2,628 | 246 | 745 | 0 |
| 31 Mar 15 | 2,566 | 235 | 718 | 0 |
| 31 Dec 14 | 2,501 | 223 | 692 | 0 |
| 30 Sep 14 | 2,418 | 213 | 676 | 0 |
| 30 Jun 14 | 2,375 | 201 | 675 | 0 |
| 31 Mar 14 | 2,310 | 186 | 677 | 0 |
| 31 Dec 13 | 2,236 | 176 | 659 | 0 |
Quality Earnings: 002262 has high quality earnings.
Growing Profit Margin: 002262's current net profit margins (21.2%) are lower than last year (21.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002262's earnings have grown by 11.9% per year over the past 5 years.
Accelerating Growth: 002262's earnings growth over the past year (12.2%) exceeds its 5-year average (11.9% per year).
Earnings vs Industry: 002262 earnings growth over the past year (12.2%) exceeded the Pharmaceuticals industry -2.5%.
Return on Equity
High ROE: 002262's Return on Equity (16.4%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 07:32 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jiangsu Nhwa Pharmaceutical Co., LTD is covered by 24 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Yanyin Zhu | China International Capital Corporation Limited |
| Shanshan Li | China Merchants Securities Co. Ltd. |